Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp351 | Osteoporosis: treatment | ECTS2014

A transdermal patch delivering the PTHrP1–34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo

Yates John , Alexandersen Peter , Krogsaa Annesofie , Nedergaard Bettina , Clarkin Marcie , Hattersley Gary , Hansen Kris , Karsdal Morten , Christiansen Claus

Abaloparatide (BA058) is a synthetic analog of PTHrP1–34 which greatly increases bone mass and bone strength with preservation of normal bone quality in animal models of osteoporosis. Daily s.c. abaloparatide (ABLSC) at doses of up to 80 μg daily in postmenopausal women with osteoporosis for up to 48 weeks were associated with increases in spine and femoral neck BMD of up to 12.9 and 4.1% respectively and good safety and tolerability. The increa...

ba0003pp352 | Osteoporosis: treatment | ECTS2014

Abaloparatide (BA058), a novel human PTHrP analog, restores bone mass and strength in the aged osteopenic ovariectomized cynomolgus monkey

Hattersley Gary , Doyle Nancy , Varela Aurore , Guldberg Robert E , Smith Susan Y

Abaloparatide (ABL) is a novel analog of hPTHrP (1–34) in clinical development for treatment of osteoporosis. This study evaluated the long-term effects of ABL on BMD and bone strength in aged osteopenic, ovariectomized (OVX) monkeys. Four groups of ≥9-year-old female cynomolgus monkeys underwent OVX and one group underwent Sham surgery. After a 9-month bone depletion period, increases in bone markers and decreases in BMD by DXA and pQCT were observed for OVX groups...

ba0003pp359 | Osteoporosis: treatment | ECTS2014

Ten year alendronate use does not adversely affect bone quality compared to 5 years use: a human iliac crest biopsy study

Hassler Norbert , Gamsjaeger Sonja , Hofstetter Birgit , Brozek Wolfgang , Misof Barbara , Roschger Paul , Klaushofer Klaus , Paschalis Eleftherios

Bisphosphonates (BPs) including alendronate (ALN) are the most widely prescribed therapy for post-menopausal osteoporosis. Despite their overall excellent safety record and efficacy in reducing fractures, concerns have been expressed lately regarding potential detrimental effects due to prolonged bone turnover reduction, although no definite cause–effect relationship has been established to date. The purpose of the present study was to determine bone material quality by R...

ba0003pp373 | Other diseases of bone and mineral metabolism | ECTS2014

Involvement of Gla rich protein with pathological calcification during osteoarthritis. Insights into its γ-carboxylation status

Rafael Marta , Cavaco Sofia , Viegas Carla , Santos Sofia , Ramos Acacio , Luis Ines , Costa Ruben , Willems Brecht , Herfs Marjolein , Theuwissen Elke , Vermeer Cees , Simes Dina

Gla-rich protein (GRP) is a vitamin K-dependent protein, characterized by a high density of γ-carboxylated Glu residues and high calcium binding affinity. It was shown to accumulate in mouse and sturgeon cartilage and in sites of skin and vascular calcification in humans. Four alternatively spliced transcripts of the GRP gene (GRP–F1, F2, F3 and F4) were described in mouse chondrocytes and zebrafish. Osteoarthritis (OA) is a common degenerative joint disease...

ba0003pp379 | Other diseases of bone and mineral metabolism | ECTS2014

Effect of mesenchymal stem cells and platelet-derived growth factor transplantation on the localized radiation-induced ulcerative lesion in rats

Jin Im Geon , Hwang Soon Jung

Purpose: Osteoradionecrosis (ORN) of the mandible is a serious complication of radiation therapy, and accompanies soft tissue damage before bone loss appears. However, there is still no adequate treatment to heal the soft tissue damage of ORN. This study investigated the effect of platelet-derived growth factor (PDGF) or rat mesenchymal stem cells (rMSCs) on the healing of radiation-induced soft tissue injury by varying administration timing.Methods: Rat...

ba0003pp412 | Paediatric bone disease | ECTS2014

Team management of young persons with osteogenesis imperfecta

Hagberg Maud , Lowing Kristina , Malmgren Barbro , Kumlien Catharina , Eva AEstrom

The pediatric osteogenesis imperfecta (OI) team at our university hospital was established in 1991. The multi- and inter-disciplinary team consists of: pediatric neurologist, nurse, nursing assistant, physiotherapist, occupational therapist, orthopedic surgeon, orthotist, radiologist, dentist and geneticist. We also have a close collaboration with other specialists.Our assignment is high qualified diagnostics, functional assessments and also individualiz...

ba0004is13 | (1) (1) | ICCBH2015

Shared therapeutic targets in genetic skeletal diseases

Briggs Michael D , Pirog Katarzyna A , Bell Peter A

Genetic skeletal diseases (GSDs) are an extremely diverse and complex group of rare genetic diseases that primarily affect the development and homeostasis of the osseous skeleton. There are more than 450 unique and well-characterised phenotypes that range in severity from relatively mild to severe and lethal forms. Although individually rare, as a group of related genetic diseases, GSDs have an overall prevalence of at least 1/4000 child. Qualitative defects in cartilage struc...

ba0004op3 | (1) | ICCBH2015

Increase of preosteoclasts and secretion of PDGF-BB by inhibition of cathepsin K activity increases mouse bone mass during development

Crane Janet , Ye Zixing , Xie Hui , Xia Zhuying , Cao Xu

Objective: Accretion of bone mass in childhood is dependent on both bone modeling and remodeling. We recently found that preosteoclasts secrete platelet derived growth factor type BB (PDGF-BB) to promote angiogenesis coupling with osteogenesis during both modeling and remodeling. As secretion of PDGF-BB by preosteoclasts can be enhanced through inhibition of cathepsin K activity to increase bone mass in adults, we explored if increase of secretion of PDGF-BB by preosteoclasts ...

ba0004op4 | (1) | ICCBH2015

Transplantation of culture-expanded bone marrow cells and platelet rich plasma in lower limb lengthening for short stature patients

Kitoh Hiroshi , Mishima Kenichi , Matsushita Masaki , Ishiguro Naoki

Objectives: We have performed a novel cell therapy using culture-expanded bone marrow cells (BMC) and platelet rich plasma (PRP) during limb lengthening procedure since 2002. In the present study, we evaluated the efficacy of the cell therapy on new bone regenerates in patients with achondroplasia (ACH) and hypochondroplasia (HCH).Methods: The transplantation technique of BMC and PRP was described previously (Bone 40: 522–528, 2007). Inclusion crite...

ba0004op10 | (1) | ICCBH2015

Does degree of adiposity influence upper limb fracture site in children?

Moon Rebecca , Lim Adelynn , Farmer Megan , Segaran Avinash , Clarke Nicholas , Harvey Nicholas , Dennison Elaine , Cooper Cyrus , Davies Justin

Although it has been suggested that overweight and obese children have an increased risk of fracture, recent studies in post-menopausal women have shown that the relationship between obesity and fracture risk varies by fracture site. Thus, obesity is protective against wrist fractures but confers an increased risk of humeral fractures. There are no data to suggest whether this observation is also present in children. We therefore assessed whether adiposity and overweight/obesi...